EC
FATE icon

EcoR1 Capital’s Fate Therapeutics FATE Stock Holding History

EcoR1 Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,049,405
Closed -$5.03M – 52
2024
Q4 		$5.03M Buy
+3,049,405
New +$7.68M 0.19% 44
2020
Q3 		– Sell
-619,855
Closed -$21.3M – 56
2020
Q2 		$21.3M Sell
619,855
-1,722,020
-74% -$51.3M 1.57% 20
2020
Q1 		$52M Buy
2,341,875
+1,890,521
+419% +$47.8M 5.43% 5
2019
Q4 		$8.83M Buy
+451,354
New +$7.17M 0.8% 27
2017
Q4 		– Sell
-2,262,678
Closed -$8.96M – 35
2017
Q3 		$8.96M Sell
2,262,678
-274,348
-11% -$933K 1.19% 22
2017
Q2 		$8.22M Hold
2,537,026
– – 1.46% 16
2017
Q1 		$11.5M Buy
+2,537,026
New +$9.28M 2.92% 11
2016
Q4 		– Sell
-590,527
Closed -$1.84M – 34
2016
Q3 		$1.84M Buy
+590,527
New +$1.43M 0.57% 28

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

EcoR1 Capital's FATE Position: Q1 2025 in Review

EcoR1 Capital sold out of Fate Therapeutics (FATE) in Q1 2025, closing a stake of 3,049,405 shares — an estimated $5.03M sold.

EcoR1 Capital first reported a position in FATE in Q3 2016 and held it in 8 quarters. The position peaked at $52M in Q1 2020. 132 funds tracked by Wall St. Rank hold FATE as of Q1 2025.

  • EcoR1 Capital reported no remaining Fate Therapeutics position as of Q1 2025 after selling out during the quarter.
  • EcoR1 Capital sold 3,049,405 Fate Therapeutics shares in Q1 2025, an estimated $5.03M.
  • EcoR1 Capital first reported a position in Fate Therapeutics in Q3 2016 and held it in 8 quarters.
  • EcoR1 Capital's Fate Therapeutics position peaked at $52M in Q1 2020.
  • 132 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2025.

Based on EcoR1 Capital's 13F filing for Q1 2025, filed 15 May 2025.